Allied Biotech Corporation (TPEX:1780)
25.45
-0.65 (-2.49%)
Jan 22, 2026, 1:52 PM CST
Allied Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 821.81 | 806.92 | 720.43 | 716.75 | 676.76 | 618.07 | Upgrade | |
Revenue Growth (YoY) | 3.86% | 12.01% | 0.51% | 5.91% | 9.50% | -3.34% | Upgrade |
Cost of Revenue | 523.94 | 548.53 | 473.99 | 445.7 | 418.71 | 376.91 | Upgrade |
Gross Profit | 297.87 | 258.38 | 246.44 | 271.05 | 258.05 | 241.15 | Upgrade |
Selling, General & Admin | 145.63 | 144.15 | 131.64 | 144.71 | 120.64 | 112.85 | Upgrade |
Research & Development | 27.35 | 26.12 | 26.09 | 24.56 | 25.74 | 24.57 | Upgrade |
Operating Expenses | 173.78 | 170.27 | 157.73 | 171.27 | 146.38 | 138.59 | Upgrade |
Operating Income | 124.09 | 88.12 | 88.71 | 99.78 | 111.67 | 102.57 | Upgrade |
Interest Expense | -17.39 | -13.96 | -12.96 | -11.75 | -11.25 | -9 | Upgrade |
Interest & Investment Income | 24.41 | 24.67 | 15.63 | 5.3 | 1.65 | 5.14 | Upgrade |
Currency Exchange Gain (Loss) | -15.59 | 30.92 | 29.88 | 88.11 | -85.55 | 0.03 | Upgrade |
Other Non Operating Income (Expenses) | 2.79 | 0.29 | 1.12 | 5.01 | 1.06 | 0.61 | Upgrade |
EBT Excluding Unusual Items | 118.3 | 130.04 | 122.38 | 186.45 | 17.58 | 99.36 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 2.33 | Upgrade |
Gain (Loss) on Sale of Assets | -0.86 | - | - | -1.59 | - | -0.23 | Upgrade |
Other Unusual Items | - | - | - | 0.17 | - | 0.07 | Upgrade |
Pretax Income | 117.45 | 130.04 | 122.38 | 185.04 | 17.58 | 101.53 | Upgrade |
Income Tax Expense | 22.85 | 29.1 | 24.97 | 38.29 | 4.54 | 22.05 | Upgrade |
Net Income | 94.59 | 100.94 | 97.41 | 146.74 | 13.04 | 79.47 | Upgrade |
Net Income to Common | 94.59 | 100.94 | 97.41 | 146.74 | 13.04 | 79.47 | Upgrade |
Net Income Growth | -10.57% | 3.62% | -33.62% | 1025.14% | -83.59% | -25.66% | Upgrade |
Shares Outstanding (Basic) | 96 | 96 | 96 | 95 | 95 | 95 | Upgrade |
Shares Outstanding (Diluted) | 96 | 96 | 96 | 96 | 95 | 95 | Upgrade |
Shares Change (YoY) | 0.31% | 0.37% | 0.20% | 0.43% | 0.05% | 0.22% | Upgrade |
EPS (Basic) | 0.98 | 1.05 | 1.02 | 1.54 | 0.14 | 0.84 | Upgrade |
EPS (Diluted) | 0.98 | 1.05 | 1.01 | 1.53 | 0.14 | 0.83 | Upgrade |
EPS Growth | -10.90% | 3.96% | -33.99% | 1018.40% | -83.52% | -25.89% | Upgrade |
Free Cash Flow | 137.63 | 196.98 | 89.71 | 109.62 | 22.44 | 2.66 | Upgrade |
Free Cash Flow Per Share | 1.43 | 2.04 | 0.94 | 1.14 | 0.23 | 0.03 | Upgrade |
Dividend Per Share | 1.000 | 1.000 | 0.850 | 1.200 | 0.500 | 0.800 | Upgrade |
Dividend Growth | 17.65% | 17.65% | -29.17% | 140.00% | -37.50% | -20.00% | Upgrade |
Gross Margin | 36.24% | 32.02% | 34.21% | 37.82% | 38.13% | 39.02% | Upgrade |
Operating Margin | 15.10% | 10.92% | 12.31% | 13.92% | 16.50% | 16.59% | Upgrade |
Profit Margin | 11.51% | 12.51% | 13.52% | 20.47% | 1.93% | 12.86% | Upgrade |
Free Cash Flow Margin | 16.75% | 24.41% | 12.45% | 15.29% | 3.32% | 0.43% | Upgrade |
EBITDA | 179.57 | 144.33 | 152.38 | 165.12 | 170.53 | 158.14 | Upgrade |
EBITDA Margin | 21.85% | 17.89% | 21.15% | 23.04% | 25.20% | 25.59% | Upgrade |
D&A For EBITDA | 55.48 | 56.21 | 63.67 | 65.34 | 58.86 | 55.57 | Upgrade |
EBIT | 124.09 | 88.12 | 88.71 | 99.78 | 111.67 | 102.57 | Upgrade |
EBIT Margin | 15.10% | 10.92% | 12.31% | 13.92% | 16.50% | 16.59% | Upgrade |
Effective Tax Rate | 19.46% | 22.38% | 20.41% | 20.70% | 25.81% | 21.72% | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.